Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference
LONDON, Oct. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Jefferies 2018 London Healthcare Conference, on November 14, at 10:40 am GMT.
A webcast of the presentation will be available on the investor relations section of the company's website: https://www.autolus.com
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com
Investor contact:
International Media Contact:
U.S. Media Contact:
S.A. Noonan Communications
JW Communications
Rx Communications Group, LLC
Susan A. Noonan
Julia Wilson
Paula Schwartz
+1-212-966-3650
+44 (0)7818 430877
+ 1-917-322-2216
susan@sanoonan.com
juliawilsonuk@gmail.com
pschwartz@rxir.com
View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-to-present-at-the-jefferies-2018-london-healthcare-conference-300740077.html
SOURCE Autolus Therapeutics plc
